Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of bevacizumab + cisplatin + pemetrexed as first-line treatment for advanced non-squamous non-small cell lung cancer
2008-006145-13Phase 2Active
- Sponsor
- Asonmec
- Start
- Oct 2008
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, cisplatin and pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Asonmec. Primary endpoint: Progression-free survival. Started Oct 2008; status: active.
02
Drugs
bevacizumabcisplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-006145-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006145-13.